DermTech, Inc. (NASDAQ:DMTK – Get Free Report) shares were down 0.9% on Tuesday . The stock traded as low as $0.60 and last traded at $0.61. Approximately 48,834 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 321,284 shares. The stock had previously closed at $0.62.
Analyst Upgrades and Downgrades
Separately, Stephens cut their price target on DermTech from $2.50 to $1.50 and set an “equal weight” rating for the company in a report on Tuesday, March 5th.
Read Our Latest Stock Report on DMTK
DermTech Trading Down 0.9 %
DermTech (NASDAQ:DMTK – Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.02). DermTech had a negative return on equity of 123.96% and a negative net margin of 659.57%. The business had revenue of $3.92 million for the quarter, compared to analysts’ expectations of $4.05 million. As a group, analysts predict that DermTech, Inc. will post -1.94 earnings per share for the current year.
Institutional Trading of DermTech
A number of institutional investors have recently added to or reduced their stakes in DMTK. Comerica Bank acquired a new position in DermTech in the 3rd quarter worth $31,000. XTX Topco Ltd acquired a new position in DermTech in the 2nd quarter worth $33,000. Advisor Group Holdings Inc. lifted its holdings in DermTech by 251.8% in the 4th quarter. Advisor Group Holdings Inc. now owns 20,090 shares of the company’s stock worth $36,000 after buying an additional 14,380 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in DermTech in the 4th quarter worth $38,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in DermTech in the 1st quarter worth $42,000. 20.45% of the stock is owned by hedge funds and other institutional investors.
About DermTech
DermTech, Inc, a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers.
Further Reading
- Five stocks we like better than DermTech
- Options Trading – Understanding Strike Price
- Silicon Motion Proves That AI in Motion Stays in Motion
- Canadian Penny Stocks: Can They Make You Rich?
- Undervalued UnitedHealth Group Won’t Be For Long
- What is the Dow Jones Industrial Average (DJIA)?
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.